NTLA

USD

Intellia Therapeutics Inc. Common Stock

$8.350+0.150 (1.829%)

السعر في الوقت الحقيقي

Healthcare

التكنولوجيا الحيوية

الولايات المتحدة

مخطط الأسعار

Loading Chart...

المقاييس الرئيسية

مقاييس السوق

أساسيات الشركة

إحصاءات التداول

مقاييس السوق

الافتتاح

$8.200

الأعلى

$8.445

الأدنى

$8.060

الحجم

9.93M

أساسيات الشركة

القيمة السوقية

864.9M

الصناعة

التكنولوجيا الحيوية

البلد

United States

إحصاءات التداول

متوسط الحجم

4.19M

البورصة

NGM

العملة

USD

نطاق 52 أسبوعاً

الأدنى $5.9الحالي $8.350الأعلى $28.18

أخبار ذات صلة

٥ يونيو ٢٠٢٥ · ٠٨:٠١ م

GlobeNewswire

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today

عرض المزيد

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

٣ يونيو ٢٠٢٥ · ١١:٣٤ ص

Analyst Upgrades

Canaccord Genuity Maintains Buy on Intellia Therapeutics, Lowers Price Target to $54

Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics with a Buy and lowers the price target from $74 to $54.

عرض المزيد

Canaccord Genuity Maintains Buy on Intellia Therapeutics, Lowers Price Target to $54

٢٩ مايو ٢٠٢٥ · ١١:١٥ ص

Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $30 Price Target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Intellia Therapeutics with a Buy and maintains $30 price target.

عرض المزيد

HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $30 Price Target

٢٠ مايو ٢٠٢٥ · ١١:٠٨ ص

Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $30 Price Target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Intellia Therapeutics with a Buy and maintains $30 price target.

عرض المزيد

١٩ مايو ٢٠٢٥ · ٠١:٣٠ م

Analyst Upgrades

Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $10 Price Target

Wedbush analyst David Nierengarten reiterates Intellia Therapeutics with a Neutral and maintains $10 price target.

عرض المزيد

Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $10 Price Target

GlobeNewswire

١٨ مايو ٢٠٢٥ · ١١:٢٥ ص

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

Deep, durable and consistent reductions in TTR were sustained at two years, following a one-time dose of nex-zClinically meaningful improvements in ATTRv-PN related outcomes observed at 24 months compared to baseline,